Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.

Nature communications·2026
Same author

Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.

Nature communications·2026
Same author

Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experience.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Augmented Reality Based 3D Modelling for Sentinel Lymph Node Localization in Cutaneous Melanoma: A Pilot Study.

Journal of surgical oncology·2026
Same author

In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

The Impact of Obesity on Operative Outcomes and Long-Term Oncological Outcomes Following Rectal Cancer Surgery: A Retrospective Single-Center Study.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Sep 16, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K

Defining an Unresectable Primary Retroperitoneal Sarcoma.

James Tai1, Eyal Mor1, Catherine Mitchell2,3

  • 1Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

ANZ Journal of Surgery
|July 10, 2025
PubMed
Summary
This summary is machine-generated.

Approximately 12% of retroperitoneal sarcomas (RPS) are unresectable at presentation. Defining resectable vs. unresectable RPS can improve patient prognostication and management strategies.

Keywords:
oncologyradiotherapyretroperitoneal sarcomasurgeryvascular

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.5K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.0K

Related Experiment Videos

Last Updated: Sep 16, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.5K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.0K

Area of Science:

  • Oncology
  • Surgical Oncology
  • Sarcoma Research

Background:

  • Retroperitoneal sarcomas (RPS) are rare, heterogeneous mesenchymal tumors.
  • Complete macroscopic en bloc resection is the only curative treatment.
  • Consensus criteria for resectable vs. unresectable RPS are lacking.

Purpose of the Study:

  • To determine the rate of resectable and unresectable primary RPS.
  • To analyze the reasons for unresectability.
  • To compare outcomes between resectable and unresectable RPS cohorts.

Main Methods:

  • Retrospective analysis of primary non-metastatic RPS patients (Jan 2017 - Mar 2023).
  • Comparison of patient and tumor details between resectable and unresectable groups.
  • Analysis of factors contributing to unresectability.

Main Results:

  • 104 patients analyzed; 91 (87.5%) resectable, 13 (12.5%) unresectable.
  • Unresectability determined pre-operatively (53.8%) or intra-operatively (46.2%).
  • Superior mesenteric vessel involvement was the most common cause (38.5%); unresectable cohort had higher mortality (84.6% vs. 8.8%).

Conclusions:

  • About 12% of primary RPS present as unresectable.
  • Pre-operative imaging often identifies unresectable disease.
  • Clear definitions for resectable/unresectable RPS are needed for improved prognostication and management.